Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cardiff Oncology ( (CRDF) ) has shared an update.
On June 17, 2025, Cardiff Oncology announced the appointment of Dr. Roger Sidhu as Chief Medical Officer, succeeding Dr. Fairooz Kabbinavar, who will remain in an advisory role. Dr. Sidhu brings over 20 years of oncology leadership experience, having previously held significant roles at Treadwell Therapeutics, Amgen, and Roivant Sciences. The company also plans to release additional clinical data from its CRDF-004 trial on July 29, 2025, which evaluates onvansertib in combination with standard care for first-line RAS-mutated mCRC. This appointment and upcoming data release are expected to advance Cardiff Oncology’s clinical development and potentially impact its market positioning.
The most recent analyst rating on (CRDF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
The overall stock score is primarily influenced by Cardiff Oncology’s challenging financial performance, marked by declining revenues and heavy reliance on external financing. While technical indicators show short-term bullish momentum, the stock’s overbought status and negative valuation metrics present significant risks.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer therapies by leveraging PLK1 inhibition. Their lead asset, onvansertib, is being evaluated in combination with standard of care therapeutics for various cancers, including RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). The company’s strategy aims to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes.
Average Trading Volume: 1,157,109
Technical Sentiment Signal: Buy
Current Market Cap: $256.8M
For a thorough assessment of CRDF stock, go to TipRanks’ Stock Analysis page.